Contract Service Directory


Gilead Sciences, Inc.





Company Headquarters

650 Cliffside Drive
San Dimas, CA 91773
United States

Contract Service Directory

    Related Content

    • Breaking News | Drug Development | Industry News
      Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

      Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

      Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization.
      09.22.21

    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      Gilead, Novo Nordisk Expand NASH Alliance

      Gilead, Novo Nordisk Expand NASH Alliance

      Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.
      Kristin Brooks 03.18.21

    • Breaking News | Collaborations & Alliances | Industry News | Parenterals | Solid Dosage/Creams/Ointments
      Gilead and Merck Ink HIV Agreement

      Gilead and Merck Ink HIV Agreement

      Collaboration to focus on oral and injectable formulations of lenacapavir and islatravir.
      Tim Wright, Editor, Contract Pharma 03.15.21


    • Breaking News | Drug Development | Industry News
      Gilead, Gritstone Enter Vax Platform Pact for HIV Cure

      Gilead, Gritstone Enter Vax Platform Pact for HIV Cure

      Aims to develop HIV-specific vaccine using Gritstone’s prime-boost vaccine platform with antigens developed by Gilead.
      Kristin Brooks 02.01.21

    • Breaking News | Industry News
      Gilead to Acquire MYR GmbH for €1.15B

      Gilead to Acquire MYR GmbH for €1.15B

      Gains Hepcludex, a first-in-class treatment for HDV; anticipates accelerated global launch as a result of the acquisition.
      Contract Pharma Staff 12.10.20

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      Gilead Bolsters Biologics Capabilities

      Gilead Bolsters Biologics Capabilities

      Licenses ProteoNic’s 2G UNic Technology Platform for production of biologics.
      Contract Pharma Staff 11.10.20


    • Breaking News | Financial Reports
      Financial Report: Gilead

      Financial Report: Gilead

      Veklury (remdesivir) revenues were $873 million in the third quarter.
      Contract Pharma Staff 10.28.20

    • Breaking News | Drug Development | Trials & Filings
      Gilead’s Remdesivir Wins FDA Approval to Treat COVID-19

      Gilead’s Remdesivir Wins FDA Approval to Treat COVID-19

      Veklury is now the first and only approved COVID-19 treatment in the U.S.
      Contract Pharma Staff 10.23.20

    • Promotions & Moves
      CROS NT Appoints President of North American Ops

      CROS NT Appoints President of North American Ops

      Paul has more than 25 years of experience serving customers and managing clinical trials
      05.30.17


    • APIs | cGMP Manufacture | Industry News
      Cambrex Expands Capacity and Capabilites in Sweden

      Cambrex Expands Capacity and Capabilites in Sweden

      Installs new multi-purpose reactors, adds continuous flow technology at Karlskoga Facility
      05.30.17

    • Collaborations & Alliances | Drug Development
      Array, BMS in Opdivo Clinical Combo Alliance

      Array, BMS in Opdivo Clinical Combo Alliance

      To investigate Array's binimetinib in combination with BMS' Opdivo and Opdivo + Yervoy regimen in colorectal cancer
      05.30.17

    • Collaborations & Alliances | Drug Development
      Janssen Biotech, Protagonist in Exclusive PTG-200 Pact

      Janssen Biotech, Protagonist in Exclusive PTG-200 Pact

      To develop, manufacture and commercialize PTG-200 for Crohn's disease and ulcerative colitis
      05.30.17


    • cGMP Manufacture | Clinical Trial Materials | Formulation Development | Industry News

      Quotient Clinical Appoints Chief Commercial Officer

      Kalim to support further expansion of global commercial footprint
      05.30.17

    • Drug Development | Industry News
      Amygdala Acquires Gilead

      Amygdala Acquires Gilead's Addiction Disorder Candidiate

      Phase II ready asset has potential to become a treatment for addiction
      02.17.17

    • Promotions & Moves

      Gilead Appoints Commercial Ops EVP

      Meyers responsible for operations in North America, Europe and Japan
      11.18.16

    • 7 Gilead Sciences

      7 Gilead Sciences

      ...
      07.11.16

    • Drug Development | Drug Discovery | Industry News

      Ligand, Gilead in OmniAb Platform Pact

      Gilead will use the OmniRat, OmniMouse and OmniFlic platforms to discover mono- and bispecific antibodies
      07.11.16

    • APIs | Breaking News | cGMP Manufacture | Facilities | Industry News | Scale-up/Technology Transfer

      PharmaChem Breaks Ground on $130M Expansion Project

      New facility is dedicated to the exclusive production of Gilead medicines.
      04.06.16

    • Promotions & Moves

      Gilead CEO Steps Down

      Milligan to succeed Martin
      02.01.16